Laboratorios Farmaceuticos Rovi SA (OTCPK:LABFF)

Q2 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Jul 24, 2025 / 08:00 AM GMT

Release Date Price: $90.61

Transcript

Key Points

Positve

Sales of the specialty pharma business increased by 13% to €237.4 million in the first half of 2025.
The specialty pharma area saw a 14% increase in sales of prescription-based pharmaceutical products.
Gross margin improved by 3 percentage points to 62.4% in the first half of 2025.
International sales represented 55% of operating revenue, indicating successful internationalization efforts.
The company received a €36.3 million aid for its late project, supporting future growth and innovation.

Negative

Total operating revenue decreased by 4% to €314.6 million in the first half of 2025.
CDMO sales fell by 35% to €77.2 million, impacting overall revenue negatively.
Net profit decreased by 10% to €39.7 million compared to the first half of 2024.
R&D expenses increased by 38%, contributing to a decrease in EBITDA by 6%.
The company expects operating revenue to decrease by a mid-single-digit percentage for the full year 2025.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROVI.MC - Laboratorios Farmaceuticos ROVI SA
Q2 2025 Laboratorios Farmaceuticos ROVI SA Earnings Call
Jul 24, 2025 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning to everybody.

Thank you for joining us today for our conference on the Robi's first half 2025 financial results.

Which will stop in a moment.

I am Javier Lopez Del Monte, Rovi is deputy Chairman and Chief Financial Officer.

To me on today's call Juan de Monte.

Rovi's Chairman and CEO and Marta Campros and head of finance.

The presentation will be followed by a Q&A session.

Therefore, if you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform.

Before we begin, let me remind you that the information presented in this call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.